ReviewInternational journal of molecular sciences2016
The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Effects of valproic acid on skeletal metabolism in children with epilepsy: a systematic evaluation and meta-analysis based on 14 studies.BMC pediatrics · 2020Pooled it
- Effect of carbamazepine on the bone health of people with epilepsy: a systematic review and meta-analysis.The Journal of international medical research · 2020Pooled it
- Thyroid-metabolic interactions in pediatric epilepsy: insights from central sensitivity indices and peripheral hormone markers.European journal of pediatrics · 2026Article
- Evaluation of bone safety and antiseizure medications: a multi-source pharmacovigilance and Mendelian randomization analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Time-Dependent Effect of Anti-seizure Medications on Bone Metabolism in Patients with Epilepsy: A Cross-Sectional Study.Neurology and therapy · 2026Article
- Individuals diagnosed with epilepsy: a fractal analysis and radiomorphometric evaluation.BMC oral health · 2026Article
- Medication-Related Impacts on Pediatric Bone Health.Journal of the Pediatric Orthopaedic Society of North America · 2025Review
- Risk Estimates of Five Adverse Outcomes Following Hip and Spine Surgery Among Children with Cerebral Palsy to Inform Peri-operative Care.Journal of the Pediatric Orthopaedic Society of North America · 2025Article
- Anti-epileptic medication induced disturbed calcium-vitamin D metabolism: A behavioral analysis using association rule mining technique.World journal of experimental medicine · 2025Article
- Comparison of offspring outcomes in women with and without epilepsy.Annals of clinical and translational neurology · 2025Article
- Adverse effects of antiseizure medications: a review of the impact of pharmacogenetics and drugs interactions in clinical practice.Frontiers in pharmacology · 2025Review
- Observational
- Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies.CNS drugs · 2024Article
- Metabolomic Profiling and In Vivo Antiepileptic Effect ofMetabolites · 2024Article
- Epileptic seizures and abnormal tooth development as primary presentation of pseudohypoparathyroidism type 1B.BMJ case reports · 2024Article
- Hormonal Changes in Women with Epilepsy.Neuropsychiatric disease and treatment · 2024Review
- Predicting phase-I metabolism of piceatannol: an in silico study.In silico pharmacology · 2024Article
- Unveiling the Multifaceted Problems Associated with Dysrhythmia.International journal of molecular sciences · 2023Review
- Clinical and Genetic Features of Dravet Syndrome: A Prime Example of the Role of Precision Medicine in Genetic Epilepsy.International journal of molecular sciences · 2023Review
- The causal effect of serum 25-hydroxyvitamin D levels on epilepsy: A two-sample Mendelian randomization study.Epilepsia open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
Epilepsy is a common neurological disorder worldwide and anti-epileptic drugs (AEDs) are always the first choice for treatment. However, more than 50% of patients with epilepsy who take AEDs have reported bone abnormalities. Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA). The induction of CYP450 isoenzymes may cause vitamin D deficiency, hypocalcemia, increased fracture risks, and altered bone turnover, leading to impaired bone mineral density (BMD). Newer AEDs, such as levetiracetam (LEV), oxcarbazepine (OXC), lamotrigine (LTG), topiramate (TPM), gabapentin (GP), and vigabatrin (VB) have broader spectra, and are safer and better tolerated than the classical AEDs. The effects of AEDs on bone health are controversial. This review focuses on the impact of AEDs on growth and bone metabolism and emphasizes the need for caution and timely withdrawal of these medications to avoid serious disabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.